











Can We Say It Better?
H. Joachim DeegEnglish is a very versatile language in which new
words are readily created and accepted. For example,
some 50 years ago, the beep-beep-beep of Sputnik I
may have caught the Cold War warriors off guard,
but not the scientists and linguists; in no time it seems,
the satellite was said ‘‘to orbit,’’ that is, to travel around
the ‘‘orb,’’ the globe on which we live. We have not
done as well with our transplantation terminology, de-
spite all of the Latin, Greek, and Anglo-Saxon roots on
which we can draw. Although we talk about ‘‘autolo-
gous transplants,’’ just reflect on this term for a mo-
ment: What are we transplanting? We actually are
giving cells back to the individual from whom they
were taken; if anything, the proper term should be
‘‘autoplantation.’’
The past 10 years have seen remarkable develop-
ments in the field of hematopoietic cell transplanta-
tion, including the approaches used to prepare
patients for transplantation so that donor-derived cells
can establish themselves in the marrow space of the pa-
tient and restore normal hematopoietic and immune
functions. The language used to describe the proce-
dures and the resulting effects has considerable room
for improvement, however.
In the early years of modern hematopoietic cell
transplantation for malignant disorders, the ability to
provide hematopoietic stem cells was used to rescue
marrow function. Patients with acute leukemia, for ex-
ample, could be treated with doses of chemotherapy or
radiation that otherwise would have been fatal due to
treatment-induced marrow failure [1]. However, stud-
ies in rodent models showed that even the highest
doses of chemotherapy or radiotherapy that could be
tolerated (ie, did not result in fatal complications otherred Hutchinson Cancer Research Center and the Univer-
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infection) were not sufficient to eradicate all leukemic
blasts [2-4]. The eventual success of transplantation
generally depended on the immunologic effects of (al-
logeneic) donor cells directed at antigens expressed on
leukemic cells in the recipient, the so-called ‘‘graft-
versus-leukemia’’ (GVL) effect. The power of such
an effect was soon confirmed in clinical studies show-
ing that patients who developed graft-versus-host dis-
ease (GVHD), particularly in its chronic form, were at
lower risk for disease progression or relapse compared
with allogeneic transplant recipients even without
clinical evidence of GVHD [5,6] or recipients of trans-
plants from syngeneic twin donors [7,8]. The high-
dose conditioning regimens used at that time, often in-
volving unfractionated total body irradiation (TBI) at
doses of 800 to 1000 cGy (which, particularly in com-
bination with chemotherapy, were considered ‘‘mye-
loablative’’) did not consistently eradicate the disease.
Whereas further dose escalation (chemotherapy, radi-
ation, or both) reduced the incidence of relapse, the
price of that gain was a substantial increase in
regimen-related mortality [9].
The impetus for the development of different,
hopefully less toxic and more effective strategies
came from several directions:
1. Results in patients who had received transplants
from allogeneic donors but relapsed with their dis-
ease after transplantation showed that the infusion
of additional donor cells (obtained from peripheral
blood) after relapse was able to reinduce (lasting) re-
missions, with the success rate depending primarily
on the patient’s underlying disease [10].
2. Other studies demonstrated that preemptive donor
lymphocyte infusion in patients considered at high
risk for relapse could prevent relapse after trans-
plantation [11].
3. Studies in animal models showed that TBI doses
much lower than those traditionally used for trans-
plantation conditioning provided sufficient immu-
nosuppression in the recipient to allow for
engraftment of cells from a major histocompatibil-
ity complex–matched donor [12].
4. Results from multiple clinical trials indicated that
transplantation of donor cells obtained from pe-
ripheral blood after pretreatment with granulocyte653
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from the marrow (peripheral blood progenitor cells
[PBPCs]) was associated with more rapid engraft-
ment and lower frequency of relapse compared
with cells harvested directly from the marrow.
These mobilized cells contain larger proportions
of T lymphocytes and carry an increased risk of
(chronic) GVHD, but also are associated with an
enhanced GVL effect [13,14]. Thus, a substantial
body of information exists suggesting the possibil-
ity of carrying out successful transplantation using
conditioning regimens of lower intensity and thus
lower toxicity, particularly when PBPCs are the he-
matopoietic stem cell source.
It is not surprising that this goal can be achieved
with more than one conditioning regimen, and by
now a large body of literature supports this concept
[15-20]. The descriptions of the various regimens are
confusing, however; for example, investigators have re-
ported on ‘‘conventional’’ compared with ‘‘mini’’
transplantations, on ‘‘high-intensity’’ versus
‘‘reduced-intensity’’ or ‘‘dose-reduced’’ conditioning
regimens, and on ‘‘myeloablative’’ versus ‘‘nonmyeloa-
blative’’ transplantations, with the recent addition of
a ‘‘submyeloablative’’ regimen [21]. This creativeness
is fascinating and entertaining, but is it useful?
In principle, all transplantations performed in pa-
tients with malignant disorders are intended to be
myeloablative, in the sense that the goal is disease erad-
ication. What differs among the various approaches
may be the strategy used to achieve this goal. If this
(ie, myeloablation) is not what we mean when we say
myeloablative, then we should find a more appropriate
and specific term. It is clear that the lower the intensity
of a conditioning regimen, the more we need to rely on
the immune effects mediated by donor cells; as noted
earlier, the requirement for such an effect was already
apparent in studies reported 3 decades ago [5]. Fur-
thermore, a mini-transplantation is ‘‘mini’’ only in
the sense that the conditioning regimen is of lower in-
tensity than regimens used historically; it is still a full
transplantation, intended to replace the patient’s mar-
row with donor-derived marrow cells, and as such is
accompanied by the risk of GVHD. Admittedly, the
frequency and severity of GVHD may be somewhat
lower than that seen in higher-dose regimens, but
GVHD remains a problem even with low-intensity
conditioning [15,22,23]. Moreover, all efforts in clini-
cal hematopoietic cell transplantation are directed, as
they should be, at improving relapse-free survival in
patients. As a part of these efforts, higher-dose condi-
tioning regimens have been continuously modified
with the aim of reducing transplantation-related toxic-
ity and improving outcome. As a result, a very broad
spectrum of conditioning regimens has emerged, rang-
ing from low-dose TBI or antibody plus chemotherapyto multidrug regimens combined with high-dose TBI.
It follows that it is simply not possible to contrast mye-
loablative with nonmyeloablative conditioning—how
myeloablative or nonmyeloablative is a given regimen?
Our goal is always to eradicate the patient’s disease and
replace the patient’s marrow (and thereby immune
function) with donor-derived cells. Unfortunately,
however, the goal of consistently achieving a state of
mixed chimerism associated with tolerance and disease
eradication has not yet been achieved.
Our responsibility is to provide patients and col-
leagues with clear information on procedures and to
offer the best available therapy, regardless of whether
the term that we use to describe the proposed strategy
was coined by our group or by someone else. I propose
that we avoid vague, confusing, and potentially
misleading terminology. I suggest that regimens be de-
scribed by their composition, for example, a low-dose
TBI (eg, 200 cGy, 2 200 cGy) plus fludarabine (eg, 3
 30 mg/m2, 5  50 mg/m2) regimen, a fludarabine
(eg, 3 30 mg/m2, 5  50 mg/m2) plus melphalan
(eg, 140 mg/m2) regimen, and so on. The physician
reader must know (and the patient is entitled to
know) the composition of each regimen and the possi-
ble side effects, both acute and delayed. Journal editors
should enforce a policy of accurately conveying to the
reader what the report describes.
I would not be surprised if someone were to sug-
gest a nomenclature committee to sort things out
and provide guidance. That would be fine, but proba-
bly would be unnecessary if we could agree to clearly
state what we mean.ACKNOWLEDGMENTS
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